Skip to main content

infliximab

 

Status: One Wales interim decision

Using the agreed starting and stopping criteria, infliximab can be made available within NHS Wales for the treatment of refractory pulmonary sarcoidosis that has not responded to corticosteroids and other immunosuppressants.

Infliximab should be prescribed on the basis of lowest acquisition cost.

The risks and benefits of the off-label use of infliximab for this indication should be clearly stated and discussed with the patient to allow informed consent.

Providers should consult the relevant guidelines on prescribing unlicensed medicines before any off-label medicines are prescribed.

In February 2023 OWMAG recommended this treatment in NHS Wales, in April 2024 there was a review of the recommendation. OWMAG found nothing new that affects the original decision.

Next review: this advice will be reviewed after 3 years or earlier if new evidence becomes available.

 One Wales Interim Decision (with start and stop criteria and evidence review): Infliximab for pulmonary sarcoidosis (OW23 2024 review) (PDF, 86Kb)

Medicine details

Medicine name infliximab
Formulation infusion
Reference number OW23
Indication

Treatment of refractory pulmonary sarcoidosis that has not responded to corticosteroids and other immunosupressants

Company various
BNF chapter Respiratory system
Submission type One Wales
Status One Wales interim decision
Advice number OW23
Date of issue February 2023
Date of last review May 2024
Follow AWTTC: